Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$3.10 USD
+0.02 (0.65%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $3.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
OVID 3.10 +0.02(0.65%)
Will OVID be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for OVID based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OVID
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
OVID: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for OVID
3 Sorry Penny Stocks to Sell in May While You Still Can
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024
Buy Rating for Ovid Therapeutics Based on Novel SE Drug Candidates OV329 and OV350
Buy Rating for Ovid Therapeutics Based on Promising Drug Trials and Strategic Partnerships
TD Cowen Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)